Pulmonary function tests (PFTs) are indispensable tools in the diagnosis and management of respiratory disorders. However, their interpretation can be complex, requiring a comprehensive understanding of respiratory physiology and clinical context. This article aims to provide a concise guide to interpreting PFTs, facilitating accurate diagnosis and effective patient management.
PFTs comprise of three primary components: spirometry, lung volumes, and diffusing capacity. Spirometry assesses the airflow through the bronchial tubes, providing key parameters such as Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1). Lung volumes reflect the total air-holding capacity of the lungs, while diffusing capacity measures the gas exchange efficiency at the alveolar-capillary interface.
The FEV1/FVC ratio is critical in spirometry interpretation. A decreased ratio (<70%) indicates obstructive lung disease, such as asthma or COPD. If the ratio is normal (>70%) but the FVC is reduced, a restrictive pattern is suggested, seen in conditions like interstitial lung disease or neuromuscular disorders.
Increased lung volumes may indicate air trapping, as seen in emphysema, while decreased volumes suggest a restrictive process. A reduced diffusing capacity can signify conditions affecting the alveolar-capillary membrane, such as pulmonary fibrosis or emphysema.
Remember, PFTs should not be interpreted in isolation but in conjunction with clinical history, physical examination, and imaging studies. This holistic approach can help differentiate between conditions with similar PFT patterns, ensuring accurate diagnosis and appropriate treatment.
Interpreting PFTs is a skill that requires a sound understanding of respiratory physiology, the ability to recognize patterns, and the capacity to integrate this information with the clinical context. With practice and ongoing learning, healthcare professionals can become adept at decoding these crucial tests, thereby enhancing patient care.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation